Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil

Biochemical Pharmacology

Volumn 79, Issue 3, 2010, Pages 455-462

  Ming, Xin ^a   Thakker, Dhiren R ^a  

^a University of North Carolina   (United States)

Author keywords

Adefovir dipivoxil; Basolateral efflux; Caco 2 cells; Intestinal absorption; MRP4

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN 4; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BASOLATERAL MEMBRANE; BIOTINYLATION; CELL STRAIN; CELL STRAIN CACO 2; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTESTINE ABSORPTION; KIDNEY TUBULE EXCRETION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE; DOGS; HUMANS; INTESTINAL ABSORPTION; KIDNEY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHONIC ACIDS;

EID: 70449635126     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.029     Document Type: Article

References (32)

1. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16 (2003) 569-596
2. Cundy K.C., Barditch-Crovo P., Walker R.E., Collier A.C., Ebeling D., Toole J., et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 39 (1995) 2401-2405
3. Barditch-Crovo P., Toole J., Hendrix C.W., Cundy K.C., Ebeling D., Jaffe H.S., et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 176 (1997) 406-413
4. Noble S., and Goa K.L. Adefovir dipivoxil. Drugs 58 (1999) 479-487 discussion 88-9
5. Annaert P., Tukker J.J., van Gelder J., Naesens L., de Clercq E., van Den Mooter G., et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. J Pharm Sci 89 (2000) 1054-1062
6. Gan L.S.L., and Thakker D.R. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 23 (1997) 77-98
7. Annaert P., Kinget R., Naesens L., de Clercq E., and Augustijns P. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm Res 14 (1997) 492-496
8. Annaert P., Van Gelder J., Naesens L., De Clercq E., Van den Mooter G., Kinget R., et al. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharm Res 15 (1998) 1168-1173
9. Kruh G.D., Belinsky M.G., Gallo J.M., and Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 26 (2007) 5-14
10. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57 (1997) 3537-3547
11. Schuetz J.D., Connelly M.C., Sun D., Paibir S.G., Flynn P.M., Srinivas R.V., et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5 (1999) 1048-1051
12. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., and Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13 (2002) 595-603
13. Zelcer N., Reid G., Wielinga P., Kuil A., van der Heijden I., Schuetz J.D., et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 371 (2003) 361-367
14. van Aubel R.A., Smeets P.H., van den Heuvel J.J., and Russel F.G. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288 (2005) F327-F333
15. Hilgendorf C., Ahlin G., Seithel A., Artursson P., Ungell A.L., and Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35 (2007) 1333-1340
16. Cundy K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36 (1999) 127-143
17. Cihlar T., Lin D.C., Pritchard J.B., Fuller M.D., Mendel D.B., and Sweet D.H. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56 (1999) 570-580
18. Imaoka T., Kusuhara H., Adachi M., Schuetz J.D., Takeuchi K., and Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71 (2007) 619-627
19. Taipalensuu J., Tornblom H., Lindberg G., Einarsson C., Sjoqvist F., Melhus H., et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299 (2001) 164-170
20. Belinsky M.G., Guo P., Lee K., Zhou F., Kotova E., Grinberg A., et al. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67 (2007) 262-268
21. Reid G., Wielinga P., Zelcer N., van der Heijden I., Kuil A., de Haas M., et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100 (2003) 9244-9249
22. Dobson P.D., and Kell D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat Rev Drug Discov 7 (2008) 205-220
23. +-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol 92 (2007) 603-619
24. Kunta J.R., and Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 5 (2004) 109-124
25. Irie M., Terada T., Okuda M., and Inui K. Efflux properties of basolateral peptide transporter in human intestinal cell line Caco-2. Pflugers Arch 449 (2004) 186-194
26. Dallas S., Schlichter L., and Bendayan R. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J Pharmacol Exp Ther 309 (2004) 1221-1229
27. Prime-Chapman H.M., Fearn R.A., Cooper A.E., Moore V., and Hirst B.H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 311 (2004) 476-484
28. Lemos C., Kathmann I., Giovannetti E., Dekker H., Scheffer G.L., Calhau C., et al. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer 123 (2008) 1712-1720
29. Mottino A.D., Hoffman T., Jennes L., and Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 293 (2000) 717-723
30. Kruh G.D., Guo Y., Hopper-Borge E., Belinsky M.G., and Chen Z.S. ABCC10, ABCC11, and ABCC12. Pflugers Arch 453 (2007) 675-684
31. Takenaka K., Morgan J.A., Scheffer G.L., Adachi M., Stewart C.F., Sun D., et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67 (2007) 6965-6972
32. Beaumont K., Webster R., Gardner I., and Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4 (2003) 461-485